

Association of Helicobacter Pylori Infection with Diabetes Mellitus in Baquba-Diyala Province

Hasan, A.SH*, Zainab H. AL-Azawi**, Shiama'a R. AL-Salihi***

ABSTRACT:

BACKGROUND:

Infection with *H. pylori* has been recognized as a public health problem worldwide. Studies to address the association of *H. pylori* infection with diabetes mellitus (DM) had yielded controversial results.

OBJECTIVE:

To figure out the association between *H. pylori* infection and DM type 1 and 2 in Baquba city, Iraq.

PATIENTS AND METHODS:

This cross-sectional case control study was conducted in Baquba-Diyala province for the period from August 2015- March 2016. 82 diabetic patients (67 with type 2 and 15 with type 1) and 23 healthy non-diabetic individuals were enrolled. The DM patients include 45 (54.9%) females and 37 (45.1%) males. The mean age $\pm$ SD of type 2 DM patients was 51.37 ± 10.84 years, while the mean age $\pm$ SD of patient with type 1 DM was 23.66 ± 6.99 years. The patients were collected from the outpatient clinic of Baquba General Teaching Hospital according to the WHO definition criteria of the DM. Blood samples were collected, sera were separated and tested for the presence of anti-*H. pylori* IgG antibody using the commercially available Enzyme-linked immunosorbent assay kit. Statistical analyses were done using the Statistical Package for Social Science (SPSS) Version 18, and P value < 0.05 was considered significant.

RESULTS:

The results showed that the anti-*H. pylori* positivity rate among patients with diabetes mellitus and controls was 35.2% and 9.5% respectively, with statistically insignificant difference ($p = 0.54$). The anti-*H. pylori* positivity rate was slightly higher in type 2 DM than in type 1 DM (29.5 % vs 5.7 %, $p = 0.9$). Diabetic male had insignificantly higher positivity rate compared to female ((29.5% vs 26.8, $p = 0.096$). Furthermore, higher positivity rate was found in the age group 30-50 years.

CONCLUSION:

The anti-*H. pylori* positivity rate is insignificantly higher among diabetes mellitus patients; particularly type 2 diabetes mellitus than non-diabetic individuals in Baquba city, Iraq.

KEYWORDS: diabetes mellitus, helicobacter pylori, insulin resistant

INTRODUCTION:

The *H. pylori*, is a Gram's negative, microaerophilic bacterium found in the stomach, and may be present in other parts of the body (Cotticelli *et al.*, 2006). Infection with *H. pylori* has been recognized as a public health problem affecting approximately 50% of the world population with more prevalence in developing countries (Leja *et al.*, 2016). *H. pylori* infection has been associated with both gastrointestinal and extragastrointestinal conditions such as peptic ulcer, gastric cancer and cardiovascular disease (Cong *et al.*, 2014; Goni and Franceschi, 2016). As one of the most common chronic bacterial

infections in the world, it coupled with the susceptibility of diabetic patients to a wide range of infections as a result of chronic elevation of blood glucose level and impairment of immune functions (Agrawal *et al.*, 2010; Marietti *et al.*, 2013). Researchers have hypothesized an association between infection with *H. pylori* and diabetes mellitus (Devrajani *et al.*, 2010; Zhou *et al.*, 2013; Feng *et al.*, 2013). On the contrary, other discordant studies have failed to confirm this hypothesis (Ugwue *et al.*, 2007; Jafarzadeh *et al.*, 2013).

Although there is no concrete evidence demonstrating that *H. pylori* play a role in diabetes, the possibility for a causal relationship is an intriguing issue. There are several lines of

*College of Medicine, Diyala University.

**College of Education for Pure Science, Diyala University.

*** College of Medicine- Diyala University.

evidence to implicate increased susceptibility to infection in diabetic patients. Firstly, a diabetes-induced impairment of cellular and humoral immunity may enhance an individual's sensitivity to *H. pylori* infection (Lassenius *et al.*, 2011). Secondly, diabetes-induced reduction of gastrointestinal motility and acid secretion may promote pathogen colonization and infection rate in the gut (Jeon *et al.*, 2012). Thirdly, altered glucose metabolism may produce chemical changes in the gastric mucosa that promote *H. pylori* colonization (Marietti *et al.*, 2013). Individuals with diabetes are more frequently exposed to pathogens than their healthy counterparts as they regularly attend hospital settings. Ultimately, *H. pylori* infection was significantly increased the prevalence of metabolic syndrome through an increase in insulin resistance (Vafaeimanesh *et al.*, 2016).

PATIENTS AND METHODS:

This cross-sectional case control study was conducted in Baquba-Diyala province for the period from August 2015- March 2016 to explore the *H. pylori* positivity rate among patients with diabetes mellitus type 1 and 2. Eighty two

diabetic patients and 23 normal healthy non-diabetic individuals were enrolled in this study. The diabetic group includes 67 patients (38 females and 29 males) with type 2 and 15 patients (7 females and 8 males) with type 1DM. The mean age $\pm$ SD of patient with type 2 DM was 51.37 ± 10.84 years, with age range 32-85 years, while the mean age $\pm$ SD of patient with type 1 DM was 23.66 ± 6.99 years with age range 12-34 years. The control group comprised of 11 females and 12 males, the mean age $\pm$ SD 28.56 ± 15.36 and the age range of control group comprised (18-42 years). Those patients were collected from the outpatient clinic of Baquba General Teaching Hospital according to WHO definition criteria of the DM (Seino *et al.*, 2010). Blood sample was collected from all participants, sera were separated and tested for the presence of anti-*H. pylori* IgG antibody using the commercially available Enzyme-linked immunosorbent assay kit (Biotech, USA). Statistical analyses were done using the Statistical Package for Social Science (SPSS) Version 18.

RESULTS:

The frequency distribution of numbers of patients and control groups was shown in table (1).

Table 1: Frequency Distribution of Study Groups by Gender.

Sex	Study groups			Total (%)
	DM type 1 (%)	DM type 2 (%)	Control group (%)	
Female	7 (6.7)	38 (36.2)	11 (10.5)	56 (53.3)
Male	8 (7.6)	29 (27.6)	12 (11.4)	49 (46.7)
Total	15 (14.3)	67 (63.8)	23 (21.9)	105 (100)

Results in Table (2) revealed the *H. pylori* infection rate in DM patients and non-diabetic healthy control was 37(35.2) and 10 (9.5) respectively. Although the

infection rate was higher in DM patients, the difference was statistically insignificant $P = 0.054$.

Table 2: *H. pylori* infection rate among the study groups.

Study groups	H. pylori infection		Total (%)
	Positive (%)	Negative (%)	
DM patients	37(35.2)	45 (42.9)	82 (78.1)
Control group	10 (9.5)	13 (12.4)	23 (21.9)
Total	47(44.8)	58 (55.2)	105 (100)

Pearson Chi-square = 0.020, $P = 0.54$ [NS]

The *H. pylori* positivity rate among patients with DM type 1, type 2 and control group were 6 (5.7%), 31 (29.5%), and 10 (9.5%) respectively. The

difference among the study groups was statistically insignificant ($P = 0.9$), table (3).

Table 3: *H. pylori* Infection Rate According To The Type of DM.

Study groups	<i>H. pylori</i> infection		Total (%)
	Positive (%)	Negative (%)	
DM type 1	6 (5.7)	9 (8.6)	15 (14.3)
DM type 2	31 (29.5)	36 (34.3)	67 (63.8)
Control group	10 (9.5)	13 (12.4)	23 (21.9)
Total	47 (44.8)	58 (55.2)	105 (100)

Pearson Chi-Square = 0.21, P = 0.9 [NS]

The rate of *H. pylori* infection among DM patients according to gender was illustrated in table (3). 22 (26.8%) of females and 25 (30.4%) of males were positive. Although the infection rate was higher in males compared to females, however, the difference was statistically insignificant (P= 0.4).

Table 3: *H. pylori* infection rate among DM patients by gender.

Gender	<i>H. pylori</i> infection		Total (%)
	Positive (%)	Negative (%)	
Female	22 (26.8)	15 (18.2)	37 (45.1)
Male	25 (30.4)	20 (24.3)	45 (54.9)
Total	47 (57.3)	35 (42.7)	82 (100)

Pearson Chi-Square = 0.096, P= 0.4 [NS]

Table (4) showed the *H. pylori* infection rate among DM patients according to age groups. The age range of control group was (18-42). Although the infection rate was higher in the age group 30-50 years compared to other age groups; However, the differences was statistically insignificant (P= 0.19).

Table 4: *H. pylori* infection rate among DM patients by age groups.

Age groups (Ys)	<i>H. pylori</i> infection		Total (%)
	Positive (%)	Negative (%)	
< 30	5 (6.1)	6 (7.3)	11 (13.4)
30-50	24 (29.3)	13 (15.9)	37 (45.1)
> 50	18 (21.9)	16 (19.5)	34 (41.5)
Total	47 (57.3)	35 (42.7)	82 (100)

Pearson Chi-square = 3.34, P= 0.19 [NS]

DISCUSSION:

Since the discovery of *H. pylori*, a variety of epidemiological studies, therapeutic trials, and case reports have evaluated the direct or indirect involvement of this bacterium in the pathogenesis of various extragastric disorders particularly DM. The present study found higher *H. pylori* infection rate in diabetics patients compared to non-diabetics healthy individuals (35.2% vs 9.5%; p = 0.54). In spite of that, the study did not support a strong association between *H. pylori* infection as determined by the presence of anti-*H. pylori* IgG and DM. Worldwide studies covering the link between *H. pylori* infection and diabetes remains controversial, as some studies indicate a higher prevalence of infection in diabetic patients (Ojetti *et al.*, 2010; Feng *et al.*, 2013; Hsieh *et al.*, 2013; Yang *et al.*, 2014),

while others report no differences (Ugwuet *al.*, 2007; Jafarzadeh *et al.*, 2013; Tamura *et al.*, 2015). In a large meta-analysis study covering forty-one studies revealed a significantly higher infection rate of *H. pylori* in patients with type 2 DM compared to control group (Zhou *et al.*, 2013). Similar meta-analyses included thirty-seven case-control studies and 2 cohort studies suggest a relationship between *H. pylori* infection and the risk of DM and diabetic nephropathy (Wang *et al.*, 2013). Moreover, a strong association between diabetic nephropathy, diabetic retinopathy and neuropathy with *H. pylori* infection was also reported (Agrawal *et al.*, 2010). These discrepancies reported concerning the association of *H. pylori* and diabetes are likely due to inconsistencies in the methods used

to define *H. pylori* positivity and diabetic status, the limited sample sizes, and adjustments for potential confounders such as age and socioeconomic status (Cong *et al.*, 2014). In addition, the accuracy of self-reported data on medical history depends on the subjects' knowledge and understanding of the relevant information, their ability to recall, and their willingness to report which also may change over time (Dai *et al.*, 2015).

Several studies have documented that gastrointestinal inflammation caused by *H. pylori* can influence the absorption of glucose and lipids, which are also abnormal in diabetes mellitus. Type 2 DM, formerly known as non-insulin-dependent diabetes mellitus or adult-onset diabetes, is a metabolic disorder that is characterized by high levels of blood glucose resulting from insulin resistance and relative insulin deficiency (Polyzoset *al.*, 2011; Vafaeimaneset *al.*, 2016). Data regarding the mechanisms underlying the pathogenesis of diabetes are complex, and there are some indications that *H. pylori* infection may contribute to the development of diabetes. Whereas insulin insensitivity is an early phenomenon, pancreatic β -cell function declines gradually over time before the onset of clinical hyperglycemia, the result of many factors that can be influenced by infection, such as insulin resistance, glucotoxicity, lipotoxicity, β -cell dysfunction, chronic inflammation, and genetic and epigenetic factors (Lassenius *et al.*, 2011; Buzas, 2014). *H. pylori* infection is known to be involved in the pathogenesis of insulin resistance, and the growing awareness of its role in diabetes is important for the early detection of glucose dysregulation and prevention of T2DM in high-risk communities (Ojettiet *al.*, 2010; Cong *et al.*, 2014). Additionally, an effective *H. pylori* eradication results significantly lowered in diabetic patients than in controls, most likely because of the large use of antibiotic in DM subjects, causing selection of resistant *H. pylori* strains and moreover, re-infection after bacterial eradication, although rarely observed in the general population, seems to be more frequent in diabetic patients than in controls (Ojettiet *al.*, 2010; Mariettiet *al.*, 2013; Cong *et al.*, 2014).

The present study also found that the *H. pylori* positivity rate was insignificantly higher among type 2 DM compared to type 1 (29.5 % Vs 5.7 %, $P = 0.9$). These results are in agreement with the majority of previous studies from various other regions of the world (Zhou *et al.*, 2013; Hsieh *et al.*, 2013; Osman *et al.*, 2016). However,

glycemic control was significantly better in type 1DM patients who were negative for *H. pylori* infection compared to their counterparts (Dai *et al.*, 2015).

CONCLUSION:

Although the current data are unable to provide concrete evidence that *H. pylorus* plays a role in diabetes mellitus, however the possibility cannot be ruled out.

REFERENCES:

1. Lassenius, M.I.; Pietilainen, K.H.; Kaartinen, K.; Pussinen, P.J.; Syrjanen, J.; Forsblom, C.; Porsti, I.; Rissanen, A.; Kaprio, J. and Mustonen, J. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. *Diabetes Care*. 2011;34:1809-15.
2. Vafaeimanes, J.; Bagherzadeh, M.; Mirzaei, A.; Parham, M.; Norouzinia, M. and Vafae, R. Effect of *Helicobacter pylori* on metabolic syndrome parameters in diabetic patients. *Gastroenterol. Hepatol. Bed Bench*. 2016 ;9:S36-S41.
3. Marietti, M.; Gasbarrini, A.; Saracco, G. and Pellicano, R. *Helicobacter pylori* infection and diabetes mellitus: the 2013 state of art. *Panminerva. Med*. 2013;55:277-81.
4. Agrawal, R.P.; Sharma, R.; Garg, D.; Pokharna, R.; Kochar, D.K. and Kothari, R.P. Role of *Helicobacter pylori* in causation of diabetic gastropathies and non-gastrointestinal complications in type 2 diabetes. *Indian J. Med. Res*. 2010 ;108:140-43.
5. Goni, E. and Franceschi, F. *Helicobacter pylori* and extragastric diseases. *Helicobacter*, 2016;21 Suppl 1:45-48.
6. Feng Wang, Juan Liu, and Zongshun Lv Association of *Helicobacter pylori* infection with diabetes mellitus and diabetic nephropathy: A meta-analysis of 39 studies involving more than 20,000 participants. *Scand. J. Infect. Dis*. December 2013; 45: 930-38
7. Ugwu, N. Ugwuja, E. Ejikeme, B. Obeka, N. *Helicobacter pylori* Seropositivity in Nigerians with Type 2 Diabetes Mellitus. *Intern. J. Trop. Med*. 2007; 4:16-24.
8. Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: A risk factor for *Helicobacter pylori* infection: A hospital based case-control study. *Int J Diabetes Dev Ctries*. 2010; 30:22-26.

9. Jafarzadeh, A.; Rezayati, M.T. and Nemati, M. *Helicobacter pylori* seropositivity in patients with type 2 diabetes mellitus in south-east of Iran. *Acta Med. Iran* 2013;51:892-96.
10. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. *Helicobacter pylori* infection is associated with an increased rate of diabetes. *Diabetes Care*. 2012;35:520-25.
11. Cotticelli, L; Borrelli, M; d'Alessio, AC; Menzione, M; Villani, A; Piccolo, G; Montella, F; Iovene, MR; Romano, M. Central serous chorioretinopathy and *Helicobacter pylori*. *Eur. J. ophthalmol.* 2006;16: 274-78.
12. Leja, M.; Axon, A. and Brenner, H. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*, 2016;21:3-7.
13. Seino, Y.; Nanjo, K.; Tajima, N.; Kadowaki, T.; Kashiwagi, A.; Araki, E.; Ito, C.; Inagaki, N.; Iwamoto, Y.; Kasuga, M.; Hanafusa, T.; Haneda, M. and Ueki, K. Committee of the Japan Diabetes society on the diagnostic criteria of diabetes mellitus, report of the committee on the classification and diagnostic criteria of diabetes mellitus. *J. Diabetes Invest.* 2010; 1:212-28.
14. Zhou X, Zhang C, Wu J, Zhang G. Association between *Helicobacter pylori* infection and diabetes mellitus: a meta-analysis of observational studies. *Diabetes Res Clin Pract.* 2013;99:200-8.
15. Ojetti, V.; Pellicano, R.; Fagoonee, S.; Migneco, A.; Berrutti, M. and Gasbarrini, A. *Helicobacter pylori* infection and diabetes. *Minerva Med.* 2010 ;101:115-19.
16. Hsieh, M.C.; Wang, S.S.; Hsieh, Y.T.; Kuo, F.C.; Soon, M.S. and Wu, D.C. *Helicobacter pylori* infection associated with high HbA1c and type 2 diabetes. *Eur J Clin Invest.* 2013;43:949-56.
17. Yang, G.H.; Wu, J.S.; Yang, Y.C.; Huang, Y.H.; Lu, F.H. and Chang, C.J. Gastric *Helicobacter Pylori* infection associated with risk of diabetes mellitus, but not prediabetes. *J. Gastroenterol. Hepatol.* 2014;14: 154-59.
18. Wang, F.; Liu, J. and Lv, Z. Association of *Helicobacter pylori* infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. *Scand. J. Infect. Dis.* 2013;45:930-38.
19. Tamura, T.; Morita, E.; Kawai, S.; Sasakabe, T.; Sugimoto, Y.; Fukuda, N.; Suma, S.; Nakagawa, H.; Okada, R.; Hishida, A.; Naito, M.; Hamajima, N. and Wakai, K. No association between *Helicobacter pylori* infection and diabetes mellitus among a general Japanese population: a cross-sectional study. *Springerplus*, 2015;4:602.
20. Cong H.; Zhen Y. and Nong-Hua L. *Helicobacter pylori* infection and diabetes: Is it a myth or fact? *World J Gastroenterol.* 2014; 20: 4607-17.
21. Dai, Y.N.; Yu, W.L.; Zhu, H.T.; Ding, J.X.; Yu, C.H. and Li, Y.M. Is *Helicobacter pylori* infection associated with glycemic control in diabetics? *World J. Gastroenterol.* 2015 ; 21:5407-16.
22. Polyzos, S.A.; Kountouras, J.; Zavos, C.; Deretzi, G. The association between *Helicobacter pylori* infection and insulin resistance: a systematic review. *Helicobacter*. 2011;16:79-88.
23. Buzas, G.M. Metabolic consequences of *Helicobacter pylori* infection and eradication. *World J. Gastroenterol.* 2014; 20:5226-34.
24. Osman, S.M.; Mubarak, S.M.; Omer, I.M., Abdullah MA. *Helicobacter pylori* infection and the onset of type 1 diabetes mellitus in Sudanese children. *Sudan J. Pediatr.* 2016;16:59-66.

